Medical Condition News

RSS

Chk1 gene alone is sufficient to kill cancer cells

Researchers at Case Western Reserve University School of Medicine have discovered a mutant form of the gene, Chk1, that when expressed in cancer cells, permanently stopped their proliferation and caused cell death without the addition of any chemotherapeutic drugs.

1 Aug 2012

Only 19% of seniors with lung disease quit smoking within two years

A recent study of adults age 50 to 85 found that only 19 percent of those diagnosed with lung disease quit smoking within two years.

1 Aug 2012

Freiburg scientist receives ERC Starting Grant for NutrImmune project

The microbiologist and immunologist Prof. Dr. Andreas Diefenbach, Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Centre, has been awarded a European Research Council "Starting Grant" for his project "NutrImmune". The ERC Starting Grant is one of Europe's most prestigious grants for young investigators.

1 Aug 2012

Head impacts, concussions may speed up brain's natural aging process

Concussions and even lesser head impacts may speed up the brain's natural aging process by causing signaling pathways in the brain to break down more quickly than they would in someone who has never suffered a brain injury or concussion.

1 Aug 2012

New drug may be useful in treating long QT syndrome

Johns Hopkins researchers have discovered a new drug that may be useful in treating a heart rhythm condition called long QT syndrome.

1 Aug 2012

People with mental health problems have lower life expectancy

People with mental health problems have a lower life expectancy, according to a large-scale population based study published today in the British Medical Journal. The findings may prompt further research into the way doctors treat patients with even mild psychological problems.

1 Aug 2012

Study aims to raise awareness of nerve transfer surgery among health care providers

A study in the August issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) by Hospital for Special Surgery researchers aims to raise awareness of this type of surgery among health care providers.

1 Aug 2012

Obesity also affects sexual and urinary health in men

As a man's waistline grows, so can his experience with sexual dysfunction and frequent urination, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The study, published in the August issue of the British Journal of Urology International (BJUI), is the first to comprehensively show that obesity in men affects not just their hearts and metabolism, but also their sexual and urinary health.

31 Jul 2012

Specific autoantibodies associated with blood vessel damage in the brain

The presence of specific autoantibodies of the immune system is associated with blood vessel damage in the brain. These findings were made by Marion Bimmler, a graduate engineer of medical laboratory diagnostics at the Max Delbr-ck Center for Molecular Medicine Berlin-Buch and Dr. Peter Karczewski of the biotech company E.R.D.E.-AAK-Diagnostik GmbH in studies on a rat model.

31 Jul 2012

OrPro to advance development of ORP-100 for treatment of cystic fibrosis

OrPro Therapeutics, Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

31 Jul 2012

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

Health Union releases results of 'Migraine In America 2012' study

Health Union, LLC, released the results of its landmark study "Migraine In America 2012" tonight via a live web conference.

31 Jul 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

Rye Radiology offers new 3D mammography that detects many breast cancers

Rye Radiology Associates, LLP, became the first facility between Manhattan and Syracuse to offer the new FDA-approved 3D mammography which finds more breast cancers than traditional mammography.

31 Jul 2012

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

31 Jul 2012

Alseres enters agreement with Navidea to license Altropane imaging agent

Alseres Pharmaceuticals, Inc. today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. to license, [123I]-E-IACFT Injection (CFT), also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease and movement disorders.

31 Jul 2012

E-nose detects malignant mesothelioma

Australian researchers have developed a breath test using an electronic nose to help diagnose malignant mesothelioma in its early stages, a potentially life-saving move.

31 Jul 2012

Opioid receptors can control metabolic response to diets high in fat and sugar

Imagine eating all of the sugar and fat that you want without gaining a pound. Thanks to new research published in The FASEB Journal, the day may come when this is not too far from reality.

31 Jul 2012

Researchers use computational analysis to identify new Achilles heel for drug-resistant breast cancer

Researchers have used computational analysis to identify a new Achilles heel for the treatment of drug-resistant breast cancer. The results, which are published in Molecular Systems Biology, reveal that the disruption of glucose metabolism is an effective therapeutic strategy for the treatment of tumours that have acquired resistance to front-line cancer drugs such as Lapatinib.

31 Jul 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012